BLU-285
Pwodwi detay
Tags pwodwi
| Gwosè pake | Disponibilite | Pri (USD) |
| 1g | Nan stock | 900 |
| 5g | Nan stock | 3600 |
| 10g | Nan stock | 6200 |
| Plis gwosè | Jwenn Quotes | Jwenn Quotes |
Non Chimik:
(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4)) ]triazin-4-yl)piperazin-1-yl)pirimidin-5-yl)ethan-1-amine
Kòd SMILES:
CN1N=CC(C2=CN3C(C(N4CCN(C5=NC=C)([C@@](C)(N))C6=CC=C(F)C=C6)C=N5)CC4)=NC= N3)=C2)=C1
Kòd InChi:
InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35( 8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H, 7-10,28H2,1-2H3/t26-/m0/s1
InChi kle:
DWYRIWUZIJHQKQ-SANMLTNESA-N
Mot:
BLU-285, BLU 285, BLU285, Avapritinib
Solibilite:Soluble nan DMSO
Depo:0 - 4 ° C pou kout tèm (jou a semèn), oswa -20 ° C pou tèm long (mwa).
Deskripsyon:
Avapritinib (BLU-285) te demontre aktivite byochimik nan vitro sou anzim mutan KIT exon 17, KIT D816V (IC50 = 0.27 nM). Aktivite selilè Avapritinib sou mutan KIT D816 mezire pa otofosforilasyon nan liy selil HMC1.2 selil leukemi selil imen an, ak liy selil mastositom sourit P815 ak IC50 = 4 ak 22 nM, respektivman. Nan selil Kasumi-1, nan (8; 21)-pozitif AML liy selil ak yon KIT exon 17 N822K mitasyon, Avapritinib pisan inibit KIT N822K mutan otofosforilasyon (IC50 = 40 nM), siyal en, osi byen ke pwopagasyon selilè (IC50 =). 75 nM) [1].
Sib: KIT
